Search research articles
Contact Us
Filters
Showing results (31-40 of 38) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 38 results.
Modern Rheumatology
|
August 17, 2022
Reasons and risk factors for discontinuation of treatment with any biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A long-term observational study
Kenya Terabe, Nobunori Takahashi, Shuji Asai, et al.
Modern Rheumatology
|
May 3, 2017
High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab
Yosuke Hattori, Toshihisa Kojima, Atsushi Kaneko, et al.
The Journal of Rheumatology
|
June 17, 2016
Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study
Yosuke Hattori, Toshihisa Kojima, Atsushi Kaneko, et al.
Modern Rheumatology
|
October 27, 2012
Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis
Toshihisa Kojima, Yuichiro Yabe, Atsushi Kaneko, et al.
Modern Rheumatology
|
August 8, 2019
Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study
Shuji Asai, Masatoshi Hayashi, Masahiro Hanabayashi, et al.
Modern Rheumatology
|
September 15, 2012
Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients
Nobunori Takahashi, Toshihisa Kojima, Kenya Terabe, et al.
Joint Bone Spine
|
June 14, 2020
Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab
Shuji Asai, Nobunori Takahashi, Masatoshi Hayashi, et al.
Clinical Rheumatology
|
September 24, 2013
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Nobunori Takahashi, Toshihisa Kojima, Atsushi Kaneko, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 38) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 38 results.
Modern Rheumatology
|
August 17, 2022
Reasons and risk factors for discontinuation of treatment with any biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A long-term observational study
Kenya Terabe, Nobunori Takahashi, Shuji Asai, et al.
Modern Rheumatology
|
May 3, 2017
High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab
Yosuke Hattori, Toshihisa Kojima, Atsushi Kaneko, et al.
The Journal of Rheumatology
|
June 17, 2016
Longterm Retention Rate and Risk Factors for Adalimumab Discontinuation Due To Efficacy and Safety in Japanese Patients with Rheumatoid Arthritis: An Observational Cohort Study
Yosuke Hattori, Toshihisa Kojima, Atsushi Kaneko, et al.
Modern Rheumatology
|
October 27, 2012
Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis
Toshihisa Kojima, Yuichiro Yabe, Atsushi Kaneko, et al.
Modern Rheumatology
|
August 8, 2019
Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study
Shuji Asai, Masatoshi Hayashi, Masahiro Hanabayashi, et al.
Modern Rheumatology
|
September 15, 2012
Clinical efficacy of abatacept in Japanese rheumatoid arthritis patients
Nobunori Takahashi, Toshihisa Kojima, Kenya Terabe, et al.
Joint Bone Spine
|
June 14, 2020
Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab
Shuji Asai, Nobunori Takahashi, Masatoshi Hayashi, et al.
Clinical Rheumatology
|
September 24, 2013
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Nobunori Takahashi, Toshihisa Kojima, Atsushi Kaneko, et al.
Page
of 4